Literature DB >> 16786122

The role of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in microcystic meningiomas.

Sun Ha Paek1, Dong Gyu Kim, Chul-Kee Park, Ji Hoon Phi, Young Yim Kim, Soo Young Im, Jeong Eun Kim, Sung-Hye Park, Hee-Won Jung.   

Abstract

We studied the expression of matrix metalloproteinases (MMP) and tissue inhibitors of matrix metalloproteinase (TIMP) in microcystic meningiomas to investigate a possible underlying mechanism for the development of microcysts and of peritumoral edema, which are frequent characteristics of this rare subtype. Between October 1995 and June 2004, 10 of 19 patients who had histologically confirmed pure microcystic meningiomas were enrolled in the study. Six patients with meningothelial meningiomas, three with atypical meningiomas, and one with a transitional meningioma were included as a control group. Immunohistochemistry with paraffin blocks and real-time RT-PCR analysis for MMP-2, MMP-9, TIMP-1, TIMP-2 and vascular endothelial growth factor (VEGF) were performed using stored frozen tissues. Compared with the control group, MMP-9 was invariably and highly expressed in immunohistochemical staining of microcystic meningiomas. MMP-2, TIMP-1, TIMP-2 and VEGF were weakly expressed or not expressed in both microcystic and non-microcystic meningiomas. Real-time RT-PCR showed increased ratios of MMP-9 to TIMP-1 in microcystic meningiomas compared with the control group (55.855 +/- 106.353 vs. 1.858 +/- 2.575, respectively; p = 0.00). The expression of MMP-2 (0.72 +/- 1.20 vs. 2.54 +/- 3.01, p = 0.01) and TIMP-2 (1.22 +/- 1.67 vs. 1.61 +/- 1.82, p = 0.02) was higher in the control group. The results suggested that the increased ratio of MMP-9 to TIMP-1 might be associated with the formation of microcysts and peritumoral edema in microcystic meningioma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786122

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

Review 1.  Pathogenesis of peri-tumoral edema in intracranial meningiomas.

Authors:  Moncef Berhouma; Timothee Jacquesson; Emmanuel Jouanneau; François Cotton
Journal:  Neurosurg Rev       Date:  2017-08-24       Impact factor: 3.042

Review 2.  Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways.

Authors:  Rosaria Viola Abbritti; Francesca Polito; Maria Cucinotta; Claudio Lo Giudice; Maria Caffo; Chiara Tomasello; Antonino Germanò; Mohammed Aguennouz
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

Review 3.  Spinal cord tumours: advances in genetics and their implications for treatment.

Authors:  Patricia L Zadnik; Ziya L Gokaslan; Peter C Burger; Chetan Bettegowda
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

Review 4.  Meningioma Tumor Microenvironment.

Authors:  Sajad Sahab-Negah; Ali Gorji
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

5.  Selection of suitable reference genes for quantitative real-time polymerase chain reaction in human meningiomas and arachnoidea.

Authors:  Christina Pfister; Marcos S Tatabiga; Florian Roser
Journal:  BMC Res Notes       Date:  2011-08-02

6.  Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema.

Authors:  Joanna Reszec; Adam Hermanowicz; Robert Rutkowski; Grzegorz Turek; Zenon Mariak; Lech Chyczewski
Journal:  Biomed Res Int       Date:  2015-03-03       Impact factor: 3.411

7.  Pseudoprogression and peritumoral edema due to intratumoral necrosis after Gamma knife radiosurgery for meningioma.

Authors:  In-Ho Jung; Kyung Won Chang; So Hee Park; Hyun Ho Jung; Jong Hee Chang; Jin Woo Chang; Won Seok Chang
Journal:  Sci Rep       Date:  2022-08-11       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.